RES-010

RES-010 is a non-coding RNA drug candidate developed by Resalis Therapeutics, designed as an antisense oligonucleotide targeting microRNA-22 (miR-22). It acts by inhibiting miR-22, a key regulator of lipid biosynthesis, mitochondrial function, and adipose tissue transformation. This mechanism aims to reduce fat mass while preserving lean body mass and enhancing energy expenditure. RES-010 is being developed primarily for the treatment of obesity and non-alcoholic fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH). The drug offers a disease-modifying approach that may complement existing therapies such as GLP-1 receptor agonists by addressing metabolic pathways beyond appetite suppression. Preclinical studies have shown promising results in reducing visceral and hepatic fat stores with potential for sustained weight loss and improved metabolic health. Currently, RES-010 is in clinical development with Phase 1 trials ongoing and plans for Phase 2 proof-of-concept studies.

Other names

RES 010RES010RES-010